Skip to main content

Table 1 HLA-binding capability of the B cell epitopse derived from HPV16 L1

From: Identification of B cell epitopes reactive to human papillomavirus type-16L1- derived peptides

Peptide

Sequence

Binding capability (%)*

  

HLA-A2

HLA-A24

9-mer

QIFNKPYWL

66.8

40.3

10-mer

AQIFNKPYWL

74.9

51.7

Flu M1

GILGFVFTL

116.7

ND

EBV

TYGPVFMCL

ND

170.6

K-Ras

KLVVVG AGGV

3.3

3.8

  1. *HLA-A2 or HLA-A24-binding capability was estimated by increase in mean fluorescence intensity (MFI), determined by flowcytometry after staining of RMA-S/A2 or RMA-S/A24 cells with anti-HLA-A2 or anti-HLA-A24 mAb, as follows; MFI increase (%) = (MFI with a given peptide – MFI without peptide)/(MFI without peptide) X 100. As positive controls, an HLA-A2-binding peptide derived from influenza virus M1 (Flu M1) or an HLA-A24-binding peptide derived from Epstein-Barr virus LMP2 (EBV) was used. As a negative control, a peptide derived from oncogene K-ras was used. ND, not determined.